Tessera Defense & Homeland Security Inc. (HLSQ): who owns it and who trades it
As of Nov 13, 2026, HLSQ insiders reported 4 open-market sales worth $8.2M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Reuven Yeganeh (Director), with $8.2M.
Latest filing Nov 13, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, HLSQ insiders reported $0 of open-market purchases and $8.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Reuven Yeganeh | Director | Sale | 530,000 | $5.00 | $2.6M | Form 4 |
| Mar 16, 2026 | Reuven Yeganeh | Director | Sale | 450,000 | $5.00 | $2.2M | Form 4 |
| Mar 13, 2026 | Reuven Yeganeh | Director | Sale | 370,000 | $5.00 | $1.9M | Form 4 |
| Mar 12, 2026 | Reuven Yeganeh | Director | Sale | 300,000 | $5.00 | $1.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Reuven Yeganeh | Director, 10% owner | – | $8.2M | Mar 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HLSQ short interest
Low short interest. 0.3% of HLSQ shares are sold short: about 1 share in 301. Over the last 4 reports the number of shares short went up 19%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 88,797 HLSQ shares were sold short, 0.3% of the shares outstanding, down 70.9% from the report before. At the average daily volume of 1.62M shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 88,797 | 0.33% | -71% | 1.62M | 1.0 |
| Oct 15, 2026 | 305,287 | 1.14% | +134% | 1.40M | 1.0 |
| Sep 30, 2026 | 130,329 | 0.49% | +75% | 1.18M | 1.0 |
| Sep 15, 2026 | 74,521 | 0.28% | -88% | 1.01M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tessera Defense & Homeland Security company events
Tessera Defense & Homeland Security filed 44 reports on Form 8-K in the last 12 months, 12 of them about an important change (leadership, listing, auditor). The latest was on Oct 23, 2026.
- Oct 23, 2026LeadershipAt the Special Meeting described in Item 5.07 below, the stockholders of the Company approved Amendment No. 2 to the Company’s 2026 Equity Incentive Plan, which the Company’s Board of Directors adopted on September 24, 2026, subject to stockholder approval. Filing
- Oct 19, 2026SharesSold new shares outside a public offering. Filing
- Oct 13, 2026AnnouncementThrough October 12, 2026, the Company has raised more than $6 million in net proceeds through its at-the-market offering program at an average net price of approximately $1.11 per share, as adjusted for the Company's one-for-ten reverse stock split which was implemented as of September 9, 2026. Filing
- Oct 7, 2026LeadershipCompensation of Chief Executive Officer As previously disclosed, Michael Oster was appointed Chief Executive Officer of Tessera Defense and Homeland Security Inc. as of March 4, 2026. Filing
- Oct 5, 2026AgreementTessera Defense and Homeland Security Inc. entered into a Line of Credit Agreement with Mandragola Ltd., a company formed under the laws of the State of Israel, pursuant to which Mandragola agreed to make available to the Company and its operating subsidiaries a revolving line of credit in an of up… Filing
- Sep 29, 2026AnnouncementShared information with investors. Filing
- Sep 25, 2026AgreementTessera Defense and Homeland Security Israel Ltd., a wholly owned subsidiary of Tessera Defense and Homeland Security Inc., entered into an Option Agreement with X S.E. Security and Defense Ltd. for the purchase of all of the shares of RT LTA Systems Ltd., held by X SE, representing 51% of the… Filing
- Sep 22, 2026AgreementTessera Defense and Homeland Security Inc. entered into Amendment No. 1 to the Share Purchase and Option Agreement dated August 5, 2026 between the Company and Mayers Ventures LLC. Filing
- Sep 15, 2026RulesChanged its bylaws or articles. Filing
- Sep 9, 2026RulesChanged its bylaws or articles. Filing
- Sep 1, 2026AnnouncementBiomX Inc. announced that it will change its corporate name to Tessera Defense and Homeland Security Inc., effective at 12:01 a.m., Eastern Time, on September 11, 2026. Filing
- Sep 1, 2026AnnouncementAmended an earlier report. Of the Original Report is restated in its entirety below. Filing
- Aug 28, 2026AnnouncementBiomX Inc. announced that it will effect a one-for-ten (1-for-10) reverse stock split of its common stock, par value $0.0001 per share. Filing
- Aug 25, 2026VoteReported shareholder vote results. Filing
- Aug 11, 2026AgreementBiomX Inc., a Delaware corporation entered into a Share Purchase and Option Agreement with Mayers Ventures LLC, a Nevada limited liability company, pursuant to which the Company agreed to purchase 324,573 shares of M.E.A. Testing Systems Ltd., an Israeli company, representing 10% of the issued and… Filing
- Jul 28, 2026AgreementAs previously disclosed, on April 10, 2026, BiomX Inc. completed the acquisition of ZorroNet Ltd., and, as part of the consideration therefor, issued to Water IO Ltd., the former owner of Zorronet, a promissory note in the original principal amount of $1.25 million, with an original maturity date… Filing
- Jul 10, 2026AnnouncementBackground As previously disclosed, on April 13, 2026, BiomX Inc. completed the acquisition of a 60% interest in Dr. Frucht Systems Ltd. from Mandragola Ltd. and, in connection with the Acquisition, the Company and Mandragola Ltd. subsequently entered into a revolving line of credit of up to $2… Filing
- Jul 2, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Jun 26, 2026VoteReported shareholder vote results. Filing
- Jun 18, 2026AnnouncementShared information with investors. Filing
- Jun 12, 2026ListingBiomX Inc. received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the NYSE American LLC. Filing
- Jun 5, 2026SharesSold new shares outside a public offering. Filing
- May 28, 2026LeadershipThe Board of Directors of BiomX Inc. appointed Mr. Roy Rousso, to serve as the. Filing
- May 5, 2026AnnouncementDESCRIPTION OF BUSINESS As used in this Report, all references to the “Company,” “we,” “our” and “us” refer to BiomX Inc. and its subsidiaries, unless otherwise indicated or the context otherwise requires. Filing
- Apr 16, 2026AnnouncementZorro Net Ltd., a wholly owned subsidiary of BiomX Inc., entered into a framework supply agreement with Israel Railways Ltd., the state-owned principal railway company responsible for all inter-city, commuter, and freight rail transport in Israel, pursuant to which Zorronet will supply Israel… Filing
- Apr 13, 2026DealThe information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
- Apr 10, 2026VoteReported shareholder vote results. Filing
- Apr 10, 2026DealThe Company completed the strategic acquisition of 100% of ZorroNet, a revenue-generating, operationally deployed Israeli AI defense technology company . The information set forth in Item 1.01 is incorporated herein by reference. Filing
- Apr 1, 2026AgreementBiomX Inc., a Delaware corporation) and Mandragola Ltd, a company formed under the laws of the State of Israel (“Mandragola), entered into an Option and Undertaking Agreement pursuant to which the Company was granted an exclusive and irrevocable option to purchase 100% of Mandragola’s shareholdings… Filing
- Mar 27, 2026ListingBiomX, Inc, a Delaware corporation, received a written notice from the NYSE American LLC indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide requiring a company to have stockholders’… Filing
- Mar 19, 2026AgreementAmendment to Warrant As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on December 29, 2025, on December 26, 2025, BiomX Inc. entered into a Securities Purchase Agreement, with an investor, pursuant to which the Company agreed to issue and sell… Filing
- Mar 11, 2026VoteReported shareholder vote results. Filing
- Mar 6, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers Resignation of Directors and Officers On March 4, 2026, Jonathan Solomon resigned (i) from the board of directors of BiomX Inc. and from all Board… Filing
- Mar 2, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
- Feb 25, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
- Feb 13, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
- Feb 10, 2026LeadershipAs described in Item 2.01 above, on February 4, 2026, BiomX Ltd.’s Chief Executive Officer, Jonathan Solomon, and Chief Financial Officer, Marina Wolfson, were notified that their role as officers of BiomX Ltd. had been terminated, retroactive to January 25, 2026. Filing
- Jan 14, 2026LeadershipThe Company consummated the previously announced private placement pursuant to the Securities Purchase Agreement, dated December 26, 2025, by and between the Company and the investor party thereto, as described further in the Company’s Current Report on Form 8-K filed by the Company on December 29… Filing
- Jan 7, 2026AgreementEnded an important agreement. Filing
- Dec 29, 2025AgreementBiomX Inc., Inc., a Delaware corporation, entered into a Securities Purchase Agreement with an investor, pursuant to which the Company agreed to issue and sell, in a private placement transaction, an aggregate of 3,300 shares of the Company’s newly created Series Y Convertible Preferred Stock, par… Filing
- Dec 11, 2025AnnouncementAs previously reported, on December 8, 2025, BiomX Inc. announced the discontinuation of its ongoing Phase 2b study, which was primarily conducted by the Company’s wholly owned Israeli subsidiary, BiomX Ltd. After evaluating the projected timelines and resources required to proceed with an… Filing
- Dec 8, 2025AnnouncementAs previously reported, on November 25, 2025, BiomX Inc. announced that an independent Data Monitoring Committee completed a safety review and recommended continuation of the Company’s Phase 2b clinical trial that is designed to test the Company’s drug candidate BX004 in treating Cystic Fibrosis… Filing
- Nov 25, 2025AnnouncementAs previously disclosed by BiomX Inc. on August 19, 2025, the U.S. Food and Drug Administration had placed a clinical hold on the Company’s Phase 2b study that is design to test the Company’s drug candidate BX004 in treating Cystic Fibrosis as the FDA reviews data submitted by the Company on a… Filing
- Nov 17, 2025SharesChanged the rights of its shareholders. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Tessera Defense & Homeland Security financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named HLSQ in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 2.7% |
| Nov 13, 2026 | Nantahala Capital Management, LLC | 13G/A | 2.7% |
| Oct 6, 2026 | Mayers Ventures LLC | 13D/A | 2.2% |
| Oct 6, 2026 | Mayers Ventures LLC | 13D/A | 2.2% |
| Oct 5, 2026 | Mandragola Ltd. | 13G | 10.0% |
| Oct 5, 2026 | Mandragola Ltd. | 13G | 10.0% |
Questions about Tessera Defense & Homeland Security Inc. (HLSQ) stock
Are HLSQ insiders buying or selling?
In the last 12 months, HLSQ insiders reported no open-market purchases and 4 sales worth $8.2M. The latest trade was on Mar 17, 2026. See every trade.
What is the short interest in HLSQ?
As of Oct 30, 2026, 88,797 HLSQ shares were sold short, 0.3% of the shares outstanding, down 70.9% from the report before. At the average daily volume of 1.62M shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.